The antibody response to RNA-related antigens such as Sm/RNP requires the endosomal RNA sensor TLR7, and this process is crucial in the development of systemic lupus erythematosus at least in animal models. The inhibitory B cell receptor CD72 is unique because it recognizes Sm/RNP and specifically inhibits the activation of Sm/RNP-reactive B cells by activating SH2-containing protein tyrosine phosphatase 1 (SHP-1). In the normal immune system, Sm/RNP-reactive B cells are tolerized by a unique mechanism that probably involves SHP-1. These self-reactive B cells appear in the peripheral lymphoid organs, differentiate into marginal zone B cells, and then undergo apoptosis without further maturation into plasma cells. Thus, CD72 is involved in the suppression of TLR7-mediated response to RNA in complexes with nuclear proteins that are resistant to nucleases, whereas free RNAs are degraded by nucleases before they encounter the endosomal RNA sensor.
Introduction
Innate immune cells such as macrophages and dendritic cells (DCs) express receptors recognizing molecules that are broadly expressed by pathogens, including nucleic acids (NAs), known as pathogenassociated molecular patterns (PAMPs). 1) These receptors are called pattern recognition receptors (PRRs), and they play a crucial role in triggering acquired immune responses as well as innate responses. Recognition of PAMPs by PRRs in innate immune cells is essential for the induction of acquired immune responses. The recognition of PAMPs activates DCs, major antigen-presenting cells, and makes them capable of presenting antigens to T lymphocyte (T cells), the event required for T cell activation (Fig. 1A) . Alternatively, upon recognition of PAMPs, innate immune cells such as macrophages produce inflammatory cytokines, including tumor necrosis factor (TNF) ,, which in turn activate DCs. Antigen presentation by DCs specifically activates T cells reactive to the antigen, and activated T cells then interact with B lymphocytes (B cells) that are stimulated by the same antigen. Through this T cell-B cell interaction, B cells are stimulated by T cellderived signals such as CD40L (CD154) essential for the survival and activation of antigen-stimulated B cells, followed by differentiation to antibodyproducing cells.
2),3) Thus, the activation of DCs by direct recognition of PAMPs by PRRs or indirectly through cytokines secreted by PAMPs-activated innate cells plays a crucial role in the activation of both T lymphocytes and B lymphocytes and production of specific antibodies to pathogens.
Antibodies to NAs and NA-related antigens are characteristically produced in systemic lupus erythematosus (SLE), a prototype systemic autoimmune disease, and play a crucial role in the pathophysiology of SLE. PRR-mediated recognition is essential for the production of autoantibodies to NAs, 4)-6) as is the case for antibody production in response to conventional antigens including pathogens. However, how PRRs are required in the production of anti-NA antibodies is distinct from that in antibody production in response to conventional antigens. In antibody responses to conventional antigens, PAMPs are involved in the activation of DCs. Once activated, DCs present various antigens, including non-PAMP antigens such as protein components of microbes, thereby triggering antibody production against various microbial antigens (Fig. 1A) . Most PRRs are expressed in B cells as well as innate cells, but PRRs expressed in B cells play an auxiliary role in antibody responses to conventional antigens. 6), 7) In contrast, PRRs in B cells especially those recognizing NAs, are specifically required for the production of anti-NA antibodies (Fig. 1B) . B cells recognize antigens via the B cell receptor (BCR) composed of membrane-bound immunoglobulin (Ig) and the signal transducing component Ig, (CD79a)/IgO (CD79b). Recognition of antigens by the BCR induces signaling through the BCR, but BCR signaling alone is not sufficient for B cell activation Microbe-derived PAMPs activate DCs directly through PRRs. Alternatively, PAMPs stimulate innate cells, including macrophages, to secrete inflammatory cytokines such as TNF,, which activate DCs. Activated DCs acquire antigen presentation activity by increasing the expression of MHC-II and the T cell co-stimulatory molecules CD80 and CD86. Antigenic peptides derived from endocytosed pathogens are presented together with MHC-II, thereby activating T cells specific to microbial antigens. B cells specific to microbial antigens recognize antigens by BCR, and present antigenic peptides together with MHC-II, which interacts with activated T cells with the same antigen specificity. Through this interaction, B cells interact with the T cell-derived co-stimulatory molecule CD40L. NA sensors are classified according to their specificity (RNA vs. DNA) and intracellular localization (endosome vs. cytosol). 10) Production of anti-NA antibodies in mouse models that spontaneously develop SLE-like autoimmune disease requires NA sensors localized in endosomes such as TLR7 and TLR9.
4)-6) TLR7 and TLR9 recognize RNA and DNA, respectively, and are required for the production of autoantibodies to RNA-related antigens and DNA, respectively. Of note, mouse lupus models no longer develop diseases in the absence of TLR7, whereas TLR9 deficiency exacerbates the disease due to compensatory enhancement of TLR7 expression. 11), 12) This result suggested that immune responses to RNA but not DNA are crucial in the development of lupus though it is not yet clear why RNA-related selfantigens but not DNA ones are pathogenic. Patients with SLE produce autoantibodies to RNA-related self-antigens such as ENA and Sm/RNP, among which Sm/RNP, a complex of RNA and nuclear antigens such as U1-SnRNP, is an endogenous ligand of TLR7. 9) Thus, immune responses to Sm/RNP appear to be important in development of lupus. This review discusses the molecular and cellular mechanisms that have been elucidated in the regulation of antibody responses to Sm/RNP.
CD72 is an inhibitory receptor that regulates the development of lupus-like disease
CD72 is a 45-kDa type II membrane protein mostly expressed in B cells. CD72 contains a C-type lectin-like domain (CTLD) in the extracellular part, and was previously reported to bind to CD5 13) and CD100. 14) CD72 also contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in the cytoplasmic region. 15 !/! C57BL/6 and CD72 !/! C57BL/6.Fas lpr/lpr mice develop moderate and severe lupus-like disease, respectively. All these data indicated that CD72 inhibits development of lupus, and that CD72 c is a functionally weak allele probably due to altered interaction with the ligand.
There are polymorphisms in human CD72, and these polymorphisms have been shown to be associated with SLE using a candidate gene analysis, 23) although association of CD72 with SLE has not yet been demonstrated by a genome-wide association study, probably because there are no known polymorphisms that considerably alter the functional activity of CD72.
CD72 specifically regulates B cell responses to Sm/RNP Although CD72 regulates the development of lupus, CD72 regulates BCR signaling only weakly when BCR is polyclonally ligated using an anti-IgM antibody. 22) In contrast, other inhibitory co-receptors such as CD22 and PIR-B strongly regulate BCR signaling induced by an anti-IgM antibody but only weakly regulate development of lupus.
24)-26) Indeed, mice deficient in CD22 or PIR-B do not develop autoimmune diseases, and develop a mild disease when combined with deficiency in other genes including Fas lpr/lpr . Our recent findings on CD72-mediated signal regulation explain why CD72 strongly regulates the development of lupus without regulating anti-IgMinduced BCR signaling. Previously, the inhibitory activity of CD72 was shown to be down-modulated by interaction with CD100. 14) However, activating ligands of CD72 were not known. We recently demonstrated that the CTLD of CD72 recognizes Sm/RNP, an RNA-related self-antigen crucial in the development of lupus, as mentioned above, but not other self-antigens including DNA. This recognition induces CD72-mediated signal inhibition in B cells that produce an anti-Sm/RNP antibody. 27) As a result, CD72 inhibits B cell responses to Sm/RNP but not a control antigen (Fig. 3A) . The detailed mechanism is as follows. When BCR interacts with Sm/RNP, Sm/RNP co-ligates BCR and CD72, thereby bringing CD72 into close proximity with BCR. This enables BCR-activated kinases such as Lyn to phosphorylate CD72 ITIM, leading to the recruitment of SHP-1 to CD72 (Fig. 3B) . Indeed, CD72 is specifically phosphorylated and associated with SHP-1 when BCR interacts with Sm/RNP but not when BCR is ligated by a control antigen. Because CD72 inhibits BCR ligation only when BCR is ligated by Sm/RNP, polyclonal BCR signaling induced by anti-IgM does not appear to be regulated by CD72. In contrast, specific inhibition of B cell responses to Sm/RNP mediated by CD72 may efficiently prevent the development of lupus because the immune response to Sm/RNP is essential for development of this disease.
As already mentioned, CD72 c is a functionally weak allele and is involved in the development of severe lupus-like disease in MRL-Fas lpr/lpr mice. SPR analysis using recombinant CD72 CTLD protein revealed that the binding affinity of CD72 c CTLD to Sm/RNP was weaker than that of CD72 a CTLD. Role of CD72 in self-non-self discrimination of NA-related antigens
NAs are crucial PAMPs, but they are also selfantigens crucial in the development of lupus. NA sensors discriminate microbial NAs from self-NAs based on structure and localization. 10) For instance, RIG-I located in the cytosol prefers blunt end 5B-triphosphate dsRNA. In the cytosol, blunt end 5B-triphosphate dsRNA is exclusively derived from bacteria or viruses and not the host. Nonetheless, NA sensors recognize self-NAs as well as microbial NAs, and recognition of self-NAs contributes to autoimmunity.
Degradation by nucleases also plays a role in self-non-self recognition of NAs. NAs released by dead cells are rapidly degraded by nucleases in tissue and blood before they are endocytosed and recognized by endosomal PPRs (Fig. 3A) , whereas microbial NAs are protected from nucleases by their localization inside microbes. Thus, endosomal localization makes NA-reactive PRRs preferentially respond to microbial NAs but not free NAs released from dead cells. Indeed, when TLR9 is expressed on the cell surface, surface TLR9 induces lupus 28) probably by recognizing NAs released from dead cells. However, NAs in complexes with nuclear proteins such as Sm/RNP are resistant to nucleases, and are capable of activating endosomal TLRs. CD72-mediated inhibition of B cell responses to Sm/RNP suppresses immune response to nucleaseresistant self NAs. Thus, CD72 plays a role in selfnon-self discrimination of NAs by suppressing immune response to nuclease-resistant self-NAs. B-1 cells are also suggested to be involved in the development of autoimmune diseases, because they produce cross-reactive autoantibodies and expand in some autoimmune disease models, including mice deficient in SHP-1 in B cells. 30) , 32) In B cells, SHP-1 mediates the inhibitory functions of various inhibitory B cell co-receptors including CD72 (Fig. 4) . Because CD72 !/! mice develop moderate lupus-like disease, 22) CD72 appears to be a major inhibitory co-receptor that activates SHP-1 to prevent autoimmunity. Of note, CD72 In contrast, these receptors recognize distinct self-antigens. CD72 recognizes Sm/RNP and inhibits autoantibody responses to self NAs. In contrast, Siglec-G recognizes sialic acid, and regulates B-1 cell expansion. T. TSUBATA [Vol. 94,cell expansion. In contrast, B-1 cells are expanded in mice deficient in Siglec-G, 26) another inhibitory B cell co-receptor, although these mice do not develop autoimmune diseases. Thus, development of lupuslike disease is not necessarily associated with B-1 cell expansion. Although both of autoimmunity and B-1 cell expansion are regulated by SHP-1, these two phenotypes are regulated by distinct inhibitory co-receptors, i.e., CD72 and Siglec-G, that activate SHP-1.
Self-tolerance of B cells reactive to Sm/RNP
It is already well established that, in healthy individuals, self-reactive B cells are either deleted, inactivated (anergy) or converted to non-self-reactive B cells by replacement of the Ig V genes (receptor editing), thereby preventing self-reactive B cells to expand and to produce autoantibodies. 33) When selfreactive B cells develop in bone marrow, they are tolerized before migration to the peripheral lymphoid organs such as the spleen and lymph nodes. However, self-tolerance of B cells reactive to Sm/RNP is somewhat distinct from that of other self-reactive B cells.
Mice transgenic for the Ig H chain 3H9 and its variants established by Weigert and colleagues are useful in analyzing the self-tolerance of B cells producing anti-nuclear autoantibodies, because these Ig H chains generate anti-nuclear antibodies by associating with various Ig L chains.
34)-36) When we analyzed the mice transgenic for the 3H9 variant, in which aspartic acid at position 56 was replaced by arginine (56R), we noticed that B cells that reacted with Sm/RNP mostly utilized a single V5, i.e., V538C, together with 56R H chain to recognize Sm/RNP. The analysis using monoclonal antibody that specifically recognizes the combination of 56R H chain and V538C revealed that Sm/RNP-reactive B cells are present at a high frequency in transitional B cells, which are peripheral B cells at the stage earlier than mature peripheral B cells, and at a lower frequency in marginal zone (MZ) B cells 37) (Fig. 5A ). Peripheral lymphoid organs contain two distinct B cell populations, i.e., follicular B cells and MZ B cells. MZ B cells are located in the MZ in the spleen and in the subcapsular sinus in lymph nodes, and play a distinct role such as antibody responses to polysaccharide antigens. 38) Because CD40L, a T cell-derived costimulatory signal, is overexpressed in patients with SLE, we generated mice overexpressing CD40L 39) and crossed them with 56R-transgenic mice. Excess CD40L expands Sm/RNP-reactive MZ B cells probably by suppressing apoptosis of these B cells, and induces their differentiation into antibody-producing cells. 37) Indeed, apoptotic Sm/RNP-reactive B cells are found in splenic MZ in 56R mice when macrophages are depleted by clodronate liposome (Fig. 5B) , indicating that Sm/RNP-reactive MZ B cells undergo apoptosis and removed by macrophages. These results indicated that Sm/RNP-reactive B cells migrate to peripheral lymphoid organs and differentiate into MZ B cells, and that Sm/RNP-reactive MZ B cells are deleted by apoptosis, thereby maintaining self-tolerance whereas excess CD40L induces survival of these self-reactive MZ B cells and autoantibody production. Self-reactive B cells that are anergized in bone marrow migrate to peripheral lymphoid organs. 40) Anergized B cells are typically localized at the border between the T cell zone and follicle but not MZ 40) in the periphery, and excess CD40L fails to reverse anergy. 41) Thus, classical anergy does not appear to be induced in Sm/RNP-reactive B cells. In contrast, CD72 recognizes Sm/RNP and activates SHP-1, 27) crucial in maintenance of anergy. 29) SHP-1 activated by CD72 in Sm/RNP-reactive B cells may cause a functionally impaired status distinct from classical anergy.
Autoimmune disease in CD72 !/! mice is accelerated by Fas lpr/lpr . 22) Fas is a transmembrane receptor that transmits pro-apoptotic signaling, and is highly expressed in germinal center B cells, 42) , 43) which extensively proliferate in follicles after activation by antigens and T cell help. Because deletion of Fas in class-switched B cells was sufficient for induction of autoimmunity, 44) Fas may be involved in apoptotic deletion of self-reactive B cells probably in germinal centers after B cells are activated and undergo class switching. Thus, CD72 and Fas appear to maintain the tolerance of self-reactive B cells in peripheral lymphoid organs at different B cell differentiation stages and by distinct mechanisms, and their deficiency synergistically induce autoimmune disease.
Conclusion
PRRs play a crucial role in activating acquired immunity by inducing antigen-presentation activity of DCs in antibody responses to conventional antigens. Although PRRs are expressed in B cells, PRRs expressed in B cells play an auxiliary role in antibody responses to conventional antigens. In contrast, PRRs especially NA-reactive TLRs expressed in B cells play a crucial role in anti-NA antibody production. This is probably because NAreactive TLRs transmit co-stimulatory signaling to activate NA-reactive B cells that recognize NAs as antigens, resulting in anti-NA autoantibody production. Although it has not been discussed in this review, PRR-mediated responses of DCs to NAs are also crucial in the development of SLE. 45 ),46) DCs uptake the complex of NA-related antigens and autoantibodies, and respond to NAs via recognition by endosomal TLRs, resulting in the production of type 1 interferon (IFN). Augmented expression of IFN-stimulated genes is the most characteristic feature of the gene expression in leucocytes from SLE patients, and is called the IFN signature. 47 ), 48) IFN appears to activate various immune cell types and contributes to the breakdown of B cell selftolerance. Thus, PRRs play a distinct role in development of SLE, i.e., activation of NA-reactive B cells for autoantibody production, and the production of IFN in DCs.
Among various NA sensors, the endosomal RNA sensor TLR7 plays a central role in the development of SLE, at least in various animal models. Although free RNA released from dead cells is rapidly degraded by nucleases, RNA complexed with nuclear proteins such as Sm/RNP is relatively resistant to nucleases and is able to interact with TLR7 in endosomes after endocytosis. Therefore, RNA-protein complexes such as Sm/RNP appear to be a major TLR7 ligands involved in the development of SLE. By specifically recognizing Sm/RNP, CD72 inhibits B cell signaling by activating SHP-1 in Sm/RNP-reactive B cells. Sm/RNP-reactive B cells are present in peripheral lymphoid tissues, but are tolerized by a distinct mechanism presumably by SHP-1 activation. Thus, CD72 maintains self-tolerance to NAs by inhibiting B cell response to Sm/RNP, which is a nucleaseresistant and pathogenic NA-related self-antigen. However, how CD72-deficiency perturbs self-tolerance and causes lupus-like disease together with Fas-deficiency is not yet fully elucidated. Further studies are needed to elucidate the cellular processes regulated by CD72 and Fas in the regulation of autoimmunity.
